Silexion Therapeutics (SLXNW) Stock: Why It's Up Today
Updated Oct 19, 2026, 4:00 PM ET · closing price
- Closed at $0.01, +11.11% vs the prior close of $0.01.
- Volume 1.57K shares, 0.0x its 50-day average (light).
- New SEC filings: DEFA14A (Oct 19, 2026).
- No new insider buys or sales reported since the prior session.
SLXNW jumps 11.1% to $0.01. Closed at $0.01, +11.11% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.03.
SLXNW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 19, 2026 — SLXNW jumps 11.1% to $0.01
- Closed at $0.01, +11.11% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.03.
- Volume was 1.57K shares, 0.0x its 50-day average of 48.06K — lighter than usual.
- 52-week range $0.01–$0.01; today's close sits at 58% of that range, 7.7% below the 52-week high.
SLXNW bull case vs bear case (from the data)
- No clear positive signal in the price trend, filings or insider data right now.
- Latest fiscal-year net income: loss of $11.91M.
- Insider selling outweighs buying: 4 sales vs 0 open-market buys among the 4 most recent reported insider trades (Form 4, last 12 months).
- Share count up 660.0% in a year (dilution).
- High volatility: average daily move of 11.1% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
SLXNW latest news & SEC filings
Every SEC filing by or about SLXNW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 19, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Oct 5, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 29, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 29, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
- Item 8.01 — Reported other events the company considers important.
Sep 28, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 28, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Sep 25, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Sep 16, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Sep 9, 2026 · Form DEFA14A — Additional proxy materials
Additional proxy materials
Aug 24, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 21, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 19, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade SLXNW
- Last results release: Aug 14, 2026 (8-K Item 2.02). Previous ones: May 18, 2026, Nov 12, 2025, Aug 12, 2025. Based on that rhythm, the next report is likely around Nov 13, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 11.11% (largest 11.1%). That is a volatile stock.
- Liquidity: about 24.82K shares (≈$149) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.01 vs a range of $0.01–$0.01 (58% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Mitchell Shirvan sold 22,818 shares on Mar 26, 2026.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 29, 2026; 8-K Sep 28, 2026.
- Share count: 5.56M shares outstanding (Aug 13, 2026), +660.0% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SLXNW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | 0.03 | 0.01 | 0.01 | 0.01 | 1.57K |
| Oct 16, 2026 | 0.03 | 0.01 | 0.01 | 0.01 | 48.06K |
About Silexion Therapeutics
Silexion Therapeutics (SLXNW) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in RAMAT GAN, Israel. State of incorporation: Cayman Islands. Fiscal year ends December 31. SEC CIK 2022416.
SLXNW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dror Yosef Abramov | Director | Feb 23, 2026 |
| Ruth Alon | Director | Feb 23, 2026 |
| Ilan Hadar | Chairman and CEO | Jun 8, 2026 |
| Ilan Levin | Director | Jan 27, 2026 |
| Avner Lushi | Director | Feb 23, 2026 |
| Shlomo Noy | Director | Feb 25, 2026 |
| Amnon Peled | Director | Feb 23, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ilan Hadar | Chairman and CEO | Jun 8, 2026 |
| Hadar Mirit Horenshtein | CFO and Secretary | Jun 8, 2026 |
| Mitchell Shirvan | CSO and CDO | Jun 8, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
| Mar 26, 2026 | Mitchell Shirvan | Sale | 22,818 | $1.36 |
SLXNW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-11.91M | 8.96 | $-10.82M |
| Dec 31, 2024 | — | $-16.52M | 394.94 | $-8.40M |
| Dec 31, 2023 | — | $-5.11M | 44.23 | $-4.53M |
Latest balance sheet: total assets $4.25M, total liabilities $4.20M, cash $2.23M (as of Jun 30, 2026).
SLXNW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 14, 2026 | 8-K Item 2.02 (results) | — |
| May 18, 2026 | 8-K Item 2.02 (results) | — |
| Nov 12, 2025 | 8-K Item 2.02 (results) | — |
| Aug 12, 2025 | 8-K Item 2.02 (results) | — |
| May 13, 2025 | 8-K Item 2.02 (results) | — |
| Mar 18, 2025 | 8-K Item 2.02 (results) | — |
| Jan 14, 2025 | 8-K Item 2.02 (results) | — |
| Nov 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Tesla (TSLA)Space Exploration Technologies (SPCX)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on SLXNW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 19, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.